University of Kentucky

UKnowledge
University of Kentucky Master's Theses

Graduate School

2004

SURFACE ELECTROMYOGRAPHY CHARACTERIZATION OF THE
LOCAL TWITCH RESPONSE ELECTED BY TRIGGER POINT
INJECTION AND SNAPPING PALPATION IN MYOFASCIAL PAIN
PATIENTS
Pei Feng Lim
University of Kentucky, pflim2@uky.edu

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Lim, Pei Feng, "SURFACE ELECTROMYOGRAPHY CHARACTERIZATION OF THE LOCAL TWITCH
RESPONSE ELECTED BY TRIGGER POINT INJECTION AND SNAPPING PALPATION IN MYOFASCIAL PAIN
PATIENTS" (2004). University of Kentucky Master's Theses. 237.
https://uknowledge.uky.edu/gradschool_theses/237

This Thesis is brought to you for free and open access by the Graduate School at UKnowledge. It has been
accepted for inclusion in University of Kentucky Master's Theses by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

ABSTRACT OF THESIS

SURFACE ELECTROMYOGRAPHY CHARACTERIZATION OF THE LOCAL TWITCH RESPONSE
ELECTED BY TRIGGER POINT INJECTION AND SNAPPING PALPATION IN MYOFASCIAL PAIN
PATIENTS

Local twitch responses (LTRs) can be elicited by snapping palpation of myofascial trigger points (TrP) or TrP
injections. Objective: To characterize the LTR elicited by TrP injection and snapping palpation on surface
electromyography (sEMG) in subjects with myofascial pain in 14 female subjects. Methods: Surface EMG electrodes
were placed around the TrP and a control site on the trapezius muscle. Then the following protocol was carried out:
tension and contraction of the ipsilateral trapezius muscle, baseline resting activity (five minutes), snapping palpation
of the TrP and the control sites, TrP injection, and final resting activity (five minutes). The following data were
recorded: pain ratings, areas of referred pain, presence of LTR, and sEMG recordings. Results: During the TrP
injection, the investigator found LTRs in only 36% of the subjects, while 64% of the subjects reported that they felt
the LTR, and the sEMG recorded only one LTR in one subject. Despite the low percentage of LTRs elicited clinically
(36%), a large number of subjects (71%) reported more than 50% immediate reduction in pain intensity after the TrP
injection. Conclusion: The sEMG is unable to register the LTR elicited by snapping palpation and TrP injection.
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1. Introduction

1.1. Myofascial Pain

Myofascial pain

1 2 3

is a muscle pain disorder characterized by the presence of trigger points (TrP) in taut muscle

bands. The taut band refers to a group of tense muscle fibers. The TrP is an area in the taut band that exhibits
exquisite spot tenderness on palpation of the taut band. Upon compression of the TrP, referred pain is often elicited in
a commonly reported pattern according to the location of the TrP and the muscle. TrPs are classified as latent or
active. While both active and latent TrPs can produce pain referral upon digital compression 4, only the active TrP
reproduces the clinical pain complaint 1 2 3 5 6 7 8 9.

Numerous theories have attempted to explain the neurophysiology of the myofascial TrP
theory proposed by Simons

2

10 11 12

. The energy crisis

states that a local energy crisis is responsible for the formation of myofascial TrPs.

Stress or trauma to muscle fibers cause the release of calcium from the sacroplasmic reticulum. This increase in
intracellular calcium causes shortening of the myofibrils and increases local metabolic activity. The shortened muscle
fibers impair local circulation resulting in ischemia and hypoxia. This sets the stage for a local area of energy crisis
(the TrP). Hubbard 13 proposed a muscle spindle hyperactivity theory which states that TrPs are located at the muscle
spindles, and the increased activity at the TrP is related to hyperactivity of the muscle spindle. On the other hand, the
end-plate hyperactivity 12 14 15 theory states that activity at the TrP is due to hyperactive extrafusal motor end plates.

1.2. Local twitch response (LTR)

The local twitch response (LTR) is a palpable and/or visible transient reflex contraction of the taut band that traverses
a TrP

2 16

. This brisk contraction of the taut band (but not the surrounding normal muscle) occurs in response to

mechanical stimulation of the TrP by snapping palpation or needling. Mense 3 stated that the LTR can be elicited from
both active and latent TrPs. The LTR is considered the most specific clinical test of a trigger point

2 17 18

. Simons

1

regarded the elicitation of a LTR by snapping palpation or needle insertion into the TrP as one of the three minor
criteria for the diagnosis of myofascial pain syndrome.

The exact neurophysiological mechanism of the LTR is unclear. Hong and Torigoe

19

investigated the

electrophysiological characteristics of the LTR in rabbit skeletal muscles. Mechanical stimulation of the rabbit TrP by

1

snapping it manually with a blunt probe, tapping it with a blunt probe driven by a solenoid device, or inserting an
electromyography (EMG) needle into the TrP produced visible and needle EMG (nEMG) demonstrable rabbit-LTRs in
the responsive bands. In the rabbit, the LTR seems to be mediated via a spinal reflex

19 20

. In a case report, Hong

21

investigated the LTR produced by snapping palpation using nEMG in a patient with complete loss of nerve conduction
involving the posterior cord of the right brachial plexus. At six months following injury, nEMG activity of the LTRs in
the third finger extensor digitorum communis muscle was significantly reduced on the paralyzed side compared with
the normal side. However, at seven, eight and seventeen months post-injury, when the sensory and motor functions had
recovered considerably, EMG activity of LTRs was similar on both sides. The author concluded that the LTR in
humans is also mediated by the spinal cord, similar to LTRs in rabbits. It is likely a polysynaptic spinal reflex activity,
but the exact pathway and interneurones involved in the spinal cord are unknown 22 16. Rivner 10 hypothesized that the
LTR may be a miniature stretch reflex.

Snapping palpation is performed with the tip of the finger pulled across the muscle fibers at a right angle to the
direction of the fibers 2. However, it is very difficult to reliably elicit a LTR by snapping palpation 6 23 24. Hong et al 25
found that LTR was more frequently elicited by needling than by palpation. They reported that LTR was elicited in
39% of the TrPs by snapping palpation, and in 100% of the TrPs by TrP injection and needling. Fricton et al

26

recorded the LTR elicited by snapping palpation of taut bands with trigger points versus normal muscle using nEMG.
Results showed that the palpable band had statistically significantly higher motor activity while the normal muscles
showed minimal or no activity. Simons & Dexter 27 28 compared the nEMG and surface EMG (sEMG) characteristics
of LTR elicited by snapping palpation and needling in nine subjects. They reported that the number, duration and
density of the discharges were the same whether the LTR was elicited by snapping palpation or needling. Very little or
no EMG activity was detected by the surface electrode compared to the intramuscular (needle) electrode.

The LTR is believed to inactivate the myofascial TrP. Electrophysiological studies have demonstrated spontaneous
electrical activity (SEA) unique to animal TrSs
noise

34

. Chen et al

35

29 30

and human TrPs

31 32 33

. This is also referred to as the endplate

studied the effect of dry needling on the SEA of the rabbit myofascial TrS using nEMG. The

authors described repetitive and rapid needle insertion into the experimental TrSs in order to elicit LTRs. Control TrSs
were stimulated by very slow needle insertion for minimal LTR elicitation. A mean of 30.2 4.7 LTRs were elicited in
the experimental TrSs, while a mean of 8.4 1.4 LTRs were elicited in the control TrS. The study concluded that rapid
needling to produce multiple LTRs resulted in statistically significant inhibition of the SEA of the TrSs, compared to
the control TrSs which were minimally needled. The authors believed that the multiple LTRs elicited were responsible

2

for the reduction in electrical activity, rather than other factors such as traumatic effects of needling (e.g. edema,
hematoma formation). Later studies showed that verapamil (calcium channel blocker) 36, phentolamine (sympatholytic
agent)

30

and botulinum toxin (Botox)

37

also effectively inhibited the SEA of the myofascial TrSs. Possibly, LTRs,

calcium channel blockers, sympatholytic agents and Botox

37 38 39 40 41 42 43 44 45

have similar ability to reduce TrP

activity.

Both dry needling

17 46 47

and injection of the TrP with local anesthetic solution

effectively alleviate myofascial pain. Esenyel et al reported

50

17 48 49 50 51

have been shown to

statistical significant reduction in pain intensity

following TrP injection at two weeks and at three months. Wreje and Brorsson’
s 52 study showed that pain reduction
persisted at two weeks following TrP injection. Considerations and recommendations regarding TrP injections have
been reported previously 53 7. Fine et al 54 reported that the effects of trigger point injections were naloxone reversible,
suggesting that the pain reduction was mediated by an endogenous opioid system. In a review article on TrP
injections, Cummings

55

concluded that the needling or placebo effect is more important than the type of agent

injected. The presence/absence of LTR was not recorded in these studies.
Hong 17 investigated the importance of the LTR in a study which compared lidocaine injection to dry needling of the
myofascial TrP. Visible and/or palpable LTR was not elicited in nine (26%) out of 35 subjects who received lidocaine
injection and eight (35%) out of 23 subjects who received dry needling. The results showed that there were little or no
immediate treatment effects in these subjects where no LTR was elicited. Further injection or needling was continued
in these subjects in an attempt to elicit the LTR because the authors felt that the lack of immediate therapeutic effect
would probably signify a lack of therapeutic effect at 2 weeks post injection. The study, however, did not investigate
the amount of pain reduction at 2 weeks in subjects in whom no LTR was elicited. Further investigation is also
needed to determine if the extensive needling described by Hong
Hong

53

17

produces tissue damage. In a separate review,

speculated that rapid insertion of the needle minimized muscle fiber damage. However, he provided no

scientific data to support this statement. In his opinion and in Simons’12 experience, LTRs were elicited more easily
if the needle was moved quickly rather than slowly. Simons 12 suggested that Hong’
s needling technique using small
needles will cause less muscle fiber trauma because when the needle elicits a LTR, the fast-out stroke withdraws the
needle from the taut band before the contracting muscle can damage itself by pulling against the needle. However,
this theory needs to be validated with further research. Also in Hong’
s study

17

, dry needling was found to require

more needle insertions to inactivate the TrP than TrP injection, and hence the former group suffered greater intensity
and longer duration of post-injection soreness.

3

Due to studies which stress the importance of the LTR during TrP injections, numerous review articles 56 57 58 59 60 61 16
5 62 63 64

on trigger point injections have recommended eliciting the LTR, and numerous research papers

65 17 25 47 66

investigating TrP injections have included eliciting the LTR as a part of their protocol. Borg-Stein and Stein
recommended repeated insertions of the needle “
until a twitch response can no longer be elicited”
. Fischer
that the LTR “
proves that the needle is on target”
. Ruane and Roberts

62

61

59

stated

stated that the LTR “
verifies correct needle

placement”
. Doggweiler-Wiygul 63 advised that the LTR was used to “
verify successful needle piercing of a TrP”
, and
routinely warns the patient that the TrP injection may cause the muscle to twitch. Schneider 60 cautioned that “
as long
as the LTR can continue to be elicited, the TrP has not been eliminated…. If the LTR is still present after the (TrP)
injection, the patient will still have pain and the TrP nodule will remain palpable”
. However, none of these claims were
substantiated by scientific data.

In fact, the LTR became so important that classification of response to TrP palpation began to incorporate the
presence or absence of LTR. In Ardic’
s study

66

comparing the effects of two techniques of electrotherapy on

myofascial pain, TrPs were classified according to a four level scale: 0 –no pain with palpation; 1- pain with
palpation but no LTR; 2- pain with palpation and LTR; and 3- LTR even with light touch. Remember that back in
1990, Simons 1 considered the elicitation of a LTR by snapping palpation or needle insertion into the TrP as one of
the three minor criteria for the diagnosis of myofascial pain syndrome. Even in 1999, the 2nd edition of Travell and
Simons’Trigger point manual 2 listed the LTR as a confirmatory rather than a essential criterion. Based on Gunn’
s 67
work on intramuscular stimulation and the belief in the therapeutic importance of the LTR, Chu reported a technique,
known as Twitch-Obtaining Intramuscular Stimulation (TOIMS), in which neurogenically evoked muscle twitches
was used to relieve myofascial pain 68

69 70 71 72

. The technique uses repetitive mechanical stimulation to elicit twitch

responses at abnormally excitable motor end-plate zones. The author believed that twitches produce exercise-induced
stretch to the shortened muscle fibers, and thus restore the muscle fibers to optimal length. The efficacy of Chu’
s
technique in the management of myofascial pain remains to be established using sound research principles. At
present, there is inadequate data to help in understanding the therapeutic effect of LTRs, if any.

In fact, numerous studies investigating the effects of TrP injections did not mention eliciting the LTR as part of their
protocol 73

74 75 76 77 54 46 48 78 52 79 80 81 82 51 50

. Nevertheless, the subjects in these studies also reported pain reduction

following the TrP injection. Moreover, Campbell

18

recommended infiltration of the TrP until the area was no longer

tender and neither mentioned the fast-in-fast-out needling technique nor the LTR.

4

Studies investigating the effect of acupuncture on myofascial TrPs have reported it’
s success in relieving myofascial
pain 83 47. Based on Hong’
s study 17, Irnich et al 47 compared the immediate effects of dry needling and acupuncture at
distant sites on neck pain. In the dry needling group, the needle was inserted and manipulated until at least one LTR
was elicited. The authors found acupuncture to be superior to dry needling. Acupuncture techniques described in these
studies did not involve elicitation of the LTR either. In a survey of 1663 American Pain Society members conducted
by Harden et al 84 in 2000, only 14.6% of the respondents felt that the LTR was essential to the diagnosis of myofascial
pain. 62.6% felt that the LTR was associated with the diagnosis and 22.8% felt that it was irrelevant to the diagnosis.

In order to study the LTR, the method of recording its presence is important. The LTR has been very well
characterized in nEMG studies in animals

19 20 35

, especially in rabbits. Both nEMG 85

21 26 27 28

and sEMG 27

28

have

been used in investigations of the LTR phenomenon in humans with myofascial pain. Objective measurement of the
LTR (e.g. using sEMG or nEMG) avoids examiner bias. The nEMG method is precise, but technique sensitive and
invasive 29 14 34 27. It is difficult to insert the recording needle electrode close enough to the TrP to measure its activity,
and yet not too close such that it disturbs the TrP activity. The very insertion of the needle electrode close to the TrP
often produces a LTR 29 36. This is a distinct disadvantage since the object of interest is the LTR. In the nEMG studies,
the LTR is described as a transient burst of EMG activity 21 27 19 20. The sEMG, on the other hand, is noninvasive, less
technique sensitive, and easy to use clinically

86

. Fujimoto and Nishizono

87

found that surface electrodes was

comparable to needle electrodes in measuring muscle contractions. In addition, surface electrodes do not interfere with
the activity of the TrP. A few studies used sEMG successfully to investigate the effect of TrP injections on muscle
activity. Hendler et al 76 recorded the resting activity of the trapezius muscle (harboring TrPs) using sEMG before and
after TrP injection in the same muscle. The authors showed that resting muscle activity in the trapezius decreased after
injection. Carlson et al

49

recorded resting sEMG activity in painful masseter muscles before and after trigger point

injection in ipsilateral trapezius TrPs. They reported reduction of resting EMG activity in masseter following trapezius
TrP injection. Neither study assessed the presence or absence of LTRs. Dexter and Simons 27 28 85 reported no or only a
distant response being recorded using the sEMG electrode to record the LTR elicited by snapping palpation and needle
penetration of the trigger point. Yet Hong’
s 17 study, which documented the LTR based on clinical observation (visible
and/or palpable LTR), reported that approximately 5-30 LTRs were elicited from the needling or lidocaine injection of
the TrP. This reveals an interesting discrepancy in these reports since one would think that sEMG should be more
sensitive in detecting muscle twitch response than the human eye or hand.

5

1.3. Objectives

The aim of this study is to characterize the LTR elicited by TrP injection and snapping palpation on sEMG in subjects
with myofascial pain. This is to determine if sEMG can be used as an objective clinical tool to study the LTR.

Copyright 2004, Pei Feng Lim
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2. Methods

2.1. Study protocol and consenting procedures

The experimental protocol, informed consent form, Health Insurance Portability and Accountability Act (HIPAA)
Authorization form, and advertisement for this study were reviewed and approved by the Human Investigational
Review Boards (IRB) of the University of Kentucky. All subjects were provided with oral and written information
describing the nature and duration of the study. Subjects’informed consent was obtained at the University of Kentucky
Orofacial Pain Center and documented on the consent form. This study was conducted between January 2003 and May
2004 at the University of Kentucky Orofacial Pain Center. One investigator carried out all procedures in the protocol.
Subjects were paid $80 for their participation in this study.

2.2. Subject recruitment and inclusion/exclusion criteria

Subjects were recruited by flyers placed at the Chandler Medical Center and the University of Kentucky campus
grounds, and from patients who sought consultation or treatment at the University of Kentucky Orofacial Pain Center.
Inclusion criteria for enrollment were: (a) female, age 18 years or older; (b) diagnosis of myofascial pain based on the
following criteria 2: exquisite spot tenderness on palpable taut muscle bands (known as a TrP) in the upper trapezius
muscle, and restriction and/or pain or stiffness on cervical range of motion; and (c) an active TrP in the upper trapezius
muscle, based on the subject’
s recognition of her pain complaint or reproduction / intensification of her usual pain on
digital compression of the TrP.

Subjects were excluded from this study if they had: (a) significant medical illness (e.g. heart disease, cancer); (b)
extreme fear of needles; (c) allergy to local anesthetics; (d) bleeding disorders or tendencies (e.g. hemophilia,
thrombocytopenia, anticoagulant therapy); (e) cognitive impairment or exhibited inadequate cooperation; (f)
fibromyalgia; (g) acute trauma and/or infection in the trapezius muscle (TrP region); (h) cervical spine injury and/or
surgery within last one year (e.g. cervical radiculopathy or myelopathy, segmental instability, fracture and/or surgery
of the cervical spine); and (i) a cardiac pacemaker or other electronic devices implanted into the body that interferes
with sEMG recording.

7

2.3. Armamentarium

Armamentarium consisted of the following (see Figure 1): skin pen, ruler, alcohol swab, sterile gauze, 1 ml of 2%
lidocaine HCl without epinephrine (Xylocaine. Lidocaine HCl injection USP. AstraZeneca LP, Wilmington, DE
19850), 27-gauge (2.5cm) needle, needle protector, sEMG electrodes (HC-1 Individual disposable silver/silver
chloride electrodes. American Biotec Corporation, 24 Browning Drive, Ossining, NY 10562), electrolyte (Staodyn
Conductive Gel. Staodynamics, Inc. Longmont, CO 80501 USA), and sEMG (MP Systems. AcqKnowledge software.
Biopac Systems, Inc. 42 Aero Camino, Goleta, CA 93117.) (see Figure 2).

2.4. Pain and medical history

All subjects were interviewed regarding their pain and medical history. Subjects were asked questions regarding the
location, onset, quality (e.g. dull, aching, sharp, shooting, burning, throbbing, etc), intensity (based on a 0 to 10
Verbal Analogue Scale (VAS), with ‘
0’being no pain and ‘
10’being the worst possible pain), frequency, and
duration of their pain. Precipitating factors, aggravating factors, relieving factors, and other associated factors were
also noted. Subjects’medical history status was also obtained.

2.5. Muscle palpation
All subjects were placed in a semi supine position throughout the examination 88. The following non-biased statement
89

was read to the subjects prior to muscle palpation: “
Sometimes when we push on sore spots in muscles you may

feel pain somewhere else. I am going to push on a sore spot in the muscle. Let me know if you feel pain in an area of
your head away from where I am pushing”
. Palpation of the upper trapezius muscle was carried out with
approximately 2 lbs. of digital pressure 90 while the subject rated the pain on palpation on a 0-3 rating scale (“
0”being
no pain/tenderness on palpation; “
1”being tenderness on palpation; “
2”being pain on palpation; and “
3”being pain
on palpation with the subject withdrawing from the external pressure applied to the muscle).

TrPs and their pattern of pain referral on palpation were charted. An active TrP in the upper trapezius muscle was
defined by the following criteria 2: exquisite spot tenderness on palpable taut muscle bands in the upper trapezius
muscle, with subject’
s recognition of her pain complaint or reproduction/intensification of her usual pain on digital
compression of the TrP. For subjects with bilateral active TrP in the trapezius muscles, the more painful side was used

8

as the experimental side. The right TrP was used as the experimental side when the subject reported same pain
intensity on both sides. The TrP was located by palpation and marked as a dot on the skin with a skin pen (see Figure
3). An ipsilateral site, 2 cm away from the TrP, but not on the same taut band, was marked as a cross on the skin. This
latter site is known as the control site.

2.6. Surface electromyography (sEMG) recording
Surface EMG recording was carried out according to the guidelines by Van Boxtel 91. The skin around the TrP and
the control site region was cleansed with alcohol. One set of sEMG electrodes (sEMG 1) was placed around TrP
(previously marked with a dot on the skin), 3 cm mesial and 3 cm distal to the TrP (see Figures 4, 6, and 7). A second
set of electrodes (sEMG 2) was similarly placed around the control site (previously marked with a cross on the skin)
(see Figures 5, 6, and 7). These electrodes were placed parallel to the trapezius muscle fibers. Each ground lead was
placed at an equal distance from the two active leads. The same set of recording electrodes, sEMG 1 and sEMG 2,
were used for all subjects. sEMG recording was continuous throughout the study. Subjects were positioned such that
they could not view the monitor of the sEMG recording. sEMG signals were amplified (gain = 1000) and passed
through a 10-5000 Hz bandpass filter. The sampling rate was 20/s.

The following records were made in the same order for all subjects: (a) a 5 second sEMG recording with the subject
tensing the ipsilateral trapezius muscle without visible shoulder movement; (b) a 5 second sEMG recording with the
ipsilateral shoulder lifted towards the subject’
s ear (see Figure 9); and (c) a 5 minute resting sEMG recording with the
subject resting quietly with her teeth apart and mandible relaxed 92 93 (see Figures 10 and 11).

2.7. Snapping palpation

Snapping palpation was performed with the tip of the investigator’
s finger pulled across the trapezius muscle fibers,
perpendicular to the direction of the fibers 2. This was carried out, with simultaneous sEMG recording, twice on the
TrP site (see Figure 12) and then twice on the control site (see Figure 13) in the same order in all subjects.
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2.8. TrP Injection

Subjects were asked to note the pattern of referred pain or pain intensification produced (if any) during the injection.
All subjects were read the following statement: “
During the injection, you may feel pain somewhere else. If you feel
pain in an area of your head away from the injection site, mark it with an ‘
X’on the drawing of the face where you
felt the pain. You may mark as many places as you wish or no place at all if there is no pain in any area away from the
injection site”
. They were also told to note the presence or absence of twitching of the trapezius muscle during the
TrP injection. The following statement was read to each subject: “
A muscle twitch is a sudden contraction of part of
the muscle. During the injection, you may feel the shoulder muscle twitch. After the injection, mark on the chart
whether or not you felt the shoulder muscle twitch”
. Subjects were instructed to record this information on a pain
diagram after the injection was carried out. They were then instructed not to move their body during the injection.

One injection was performed at the TrP site for each subject, with simultaneous sEMG recording. The TrP site was
cleansed with an alcohol swab (see Figure 14) . Then, the TrP was framed by two fingers flat on the muscle (see
Figure 15) . Following that, local anesthetic was injected while using the tip of the needle to penetrate the TrP in a
fast-in-fast-out manner 2 (see Figure 16). The presence of any LTR (visible and/or palpable) during the injection was
noted by the investigator, and then recorded on the chart after the injection. Post injection hemostasis was achieved by
firm compression of the injection site for 10-15 seconds (see Figure 17).

2.9. Post-injection procedures

Following the TrP injection, resting sEMG was recorded for 5 minutes with the subject resting quietly with her teeth
apart and mandible relaxed. sEMG electrodes were removed after recording. A pain diagram was then presented to
the subject for the purpose of drawing the pattern of referred pain or pain intensification produced during the injection
(if any), and for documenting the subject’
s perception of the presence or absence of twitching of the trapezius muscle
during the TrP injection. The subjects were blinded to the investigator’
s record of the presence or absence of LTR
during the TrP injection. The investigator was also blinded to the subject’
s record of the presence or absence of LTR.
Finally, subjects were asked to state their current pain intensity on a 0 to 10 VAS (‘
0’being no pain; ‘
10’being the
worst possible pain).
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2.10. Statistical analysis

Statistical analyses were performed with SPSS for windows 11.5 program (SPSS Inc., Chicago, IL). The data were
analyzed using Student’
s t-tests and Pearson’
s correlation coefficients. Significance level was set at p<0.05 for all
analyses.

Figure 1. Armamentarium (see text for description).

Figure 2. sEMG equipment.
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Figure 3. TrP site marked as a dot and control site marked as a cross on the skin.

Figure 4. Sites marked for the placement of sEMG electrodes 3cm mesial and 3cm distal to the TrP (white
arrows).

Figure 5. Sites marked for the placement of sEMG electrodes 3cm mesial and 3cm distal to the control site
(white arrows).
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Figure 6. Sites marked for the placement of sEMG electrodes.

Figure 7. Placement of sEMG 1 around the TrP.

Figure 8. Placement of sEMG 1 and sEMG 2 around the TrP and the control sites.

13

Figure 9. sEMG recording with the subject lifting her shoulder towards her ear.

Figure 10. sEMG recording with the subject resting quietly.

Figure 11. sEMG recording monitor.
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Figure 12. Snapping palpation on the TrP site.

Figure 13. Snapping palpation on the control site.

Figure 14. TrP site cleansed with an alcohol swab.
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Figure 15. Framing the TrP with two fingers flat on the muscle.

Figure 16 (a) and (b). TrP injection carried out in a fast-in-fast-out manner.

(a)

(b)

Figure 17. Post injection hemostasis achieved by firm compression of the injection site.

Copyright 2004, Pei Feng Lim
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3. Results

3.1. Demographic and medical history data

Of the 17 subjects recruited for this study, three subjects were excluded due to incorrect recording of a defective
control sEMG electrode (sEMG 2), which was subsequently replaced. The mean age of the remaining 14 subjects was
32.9 years with a range of 23 –50 years. Eight (57%) of these subjects were married and 10 (71%) of them were
employed. None were reportedly disabled or involved in litigation. Four (29%) subjects were smokers, three (21%)
subjects consumed alcohol regularly, and 13 (93%) subjects consumed caffeinated beverages daily.

Table 1 shows the various medical disorders reported by these subjects. Eight (57%) subjects reported sinus trouble.
At the time of the study, three (21%) subjects were being treated for both anxiety disorders and depression, and one
(7%) subject was treated for depression only. None of the subjects reported to be pregnant. Table 2 shows the
subjects’current medications.

Table 3 lists the number of subjects who responded positively to the seven questions related to sleep in the Pain
Questionnaire (see Appendix 4). Eight (57%) subjects responded positively to three or more of the seven questions.
One (7%) subject responded positively to all, whilst another responded positively to none, of the sleep questions.

Table 4 lists the number of subjects who responded positively to the nine questions related to stress in the Pain
Questionnaire (see Appendix 4). Five (36%) subjects responded positively to four or more of the questions. Two
(14%) subjects did not endorse any of the questions.
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Table 1. Medical disorders.
Medical disorder

Number of subjects (%)

Sinus trouble

8 (57%)

Hay fever

4 (29%)

Depression

4 (29%)

Anxiety disorder

3 (21%)

Anemia

3 (21%)

Vision problems

3 (21%)

Table 2. Current medications.
Medications

Number of subjects (%)

Antidepressant

5 (36%)

Oral contraceptive

4 (29%)

NSAIDs

4 (29%)

Muscle relaxant

3 (21%)

Antihistamine

3 (21%)

Benzodiazepine

3 (21%)

Narcotic analgesic

1 ( 7%)

Table 3. Questions related to sleep in the pain questionnaire.
Question

Number of subjects who responded
positively to the question (%)

Do not feel rested in the morning

10 (71%)

Do not sleep well

6 (43%)

Restless sleeper

6 (43%)

Pain interferes with sleep

5 (36%)

Awaken frequently during the night

5 (36%)

Vivid dreams or nightmares

4 (29%)

Go to bed more tired than daily activities justify

2 (14%)
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Table 4. Questions related to stress in the pain questionnaire.
Question

Number of subjects who responded
positively to the question (%)

Stress makes the pain worse

11 (79%)

Feel I am under stress much of the time

10 (71%)

My hands and feet are often cold or hard to

6 (43%)

keep warm
The pain prevents me from performing my

4 (29%)

normal activities
Feel lightheaded or dizzy

3 (21%)

Feel depressed much of the time

2 (14%)

Have been under the care of a psychiatrist or

2 (14%)

psychologist
Do not enjoy my job

1 (7%)

There are times when I feel as though I cannot

1 (7%)

breathe in enough air

19

3.2. Pain characteristics

Although all subjects had an active TrP in their trapezius muscle, only nine (64%) subjects presented with neck and
shoulder pain. Nine (64%) subjects had headaches (three temporal, one frontal, two fronto-temporal, one temporaloccipital, one frontal and retro-ocular, one occipital), four (29%) subjects had face pain (two subjects reported pain in
the masseter region and two subject reported in the mandibular region), and one (7%) subject reported an earache.

Five (36%) subjects presented with unilateral pain, and nine (64%) subjects had bilateral pain. Four of the latter
subjects reported the same pain intensity on both sides and hence, their right side was used as the experimental side.
The mean pain intensity at baseline was a mean of 5.6/10 (s.d. = 1.91) ranging between 3–9/10. There was a
statistically significant negative correlation (Pearson’
s correlation; p = 0.027; r = -0.588) between the initial pain
intensity and the mean baseline resting sEMG activity at the TrP site (sEMG 1), i.e. subjects who reported higher
initial pain intensity had lower muscle activity at the TrP site. There was no significant correlation (Pearson’
s
correlation; p = 0.376; r = 0.257) between the initial pain intensity and the mean baseline resting sEMG activity at the
control site (sEMG 2).

3.3. sEMG data

Muscle activity at the control site remained largely unchanged from the baseline resting record to the final resting
record (see Table 5). However, there was a statistically significant decrease in the muscle activity from the baseline to
the final resting activity (t-test; p = 0.008). The mean sEMG activity during contraction was three times higher than
that during the mean baseline resting activity.

Muscle activity at the TrP site (see Table 6) showed a significant increase from the baseline resting activity during
palpation of the TrP site (t-test; p = 0.013) and during the TrP injection (t-test; p = 0.002). Muscle activity during the
TrP injection was also statistically significantly higher than during the final resting activity (t-test; p = 0.001). The
mean sEMG activity during contraction was 7.5 times higher than that during the mean baseline resting activity.

The sEMG data for all subjects during snapping palpation of the TrP and control sites and during the TrP injection are
shown on Figure 18. We did not observe a trend in the sEMG tracings on sEMG 1 (electrode placed around the TrP
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site) and sEMG 2 (electrode placed around the control site) during snapping palpation of the TrP and control sites,
and during the TrP injection.

The sEMG tracings did not show any burst in activity in the electrode around the TrP site (sEMG 1) relative to the
electrode around the control site (sEMG 2) during snapping palpation of the TrP and the control sites. In fact, in
Subject 1, a burst of activity was recorded at the control site (sEMG 2) when snapping palpation was performed at the
TrP site. Only in Subject 13 did there appear to be a burst of activity at the TrP site (sEMG 1) compared to the control
site (sEMG 2) during snapping palpation of the TrP site. The sEMG tracings at sEMG 1 and sEMG 2 appeared
similar in subjects 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 14 during snapping palpation of the TrP site.

There was no observable trend in the sEMG tracing during the TrP injection. Subject 1’
s sEMG 1 tracing appeared to
have captured a burst of activity at the TrP site without a corresponding burst of activity at the control site (sEMG 2).
But both the investigator and the subject failed to record a LTR (Table 7). The sEMG tracing in Subject 6 shows a
burst of activity at sEMG 1 but no corresponding burst of activity at sEMG 2. For this subject, both the investigator
and the subject indicated that the LTR was present during the TrP injection (Table 7). This seemed to be the only
subject in whom the LTR was both clinically present, as recorded by the investigator and subject, and appeared as a
burst of activity at the TrP site only (sEMG 1) on sEMG recording. The sEMG tracings of the TrP site (sEMG 1) and
the control site (sEMG 2) appeared similar in subjects 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14 during the TrP injection.
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Table 5. sEMG recording at the control site (sEMG 2).
Mean (V)

s.d. (V)

Range (V)

50.34

12.42

44.50 – 91.90

137.46

105.55

46.90 –390.40

5 min baseline resting

45.58

0.87

44.60 – 48.30

Palpation of TrP site

45.57

1.59

42.60 – 48.70

Palpation of control site

45.86

1.39

44.10 – 48.70

TrP injection

45.47

0.72

44.40 – 46.90

5 min final resting

45.39

0.89

44.20 – 48.00

5 sec tension
5 sec contraction

Table 6. sEMG recording at the TrP site (sEMG 1).
Mean (V)

s.d. (V)

Range (V)

5 sec tension

12.75

5.13

6.90 – 26.90

5 sec contraction

55.21

46.13

16.80 –188.70

5 min baseline resting

7.41

0.50

6.80 – 8.40

Palpation of TrP site

8.64

1.80

5.50 –11.20

Palpation of control site

7.88

1.16

6.20 –10.10

TrP injection

8.13

0.81

6.70 – 9.50

5 min final resting

7.36

0.59

6.70 – 8.80
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Table 7. Presence or absence of LTR based on investigator (a) and subject’
s (b) evaluation; (c) subject’
s report
of the presence/absence of referred pain; and (d) subjects reporting 50% decrease in pain intensity on the
VAS. ‘
+’indicates present; ‘
-’indicates absence.

Subject (a) Investigator (b) Subject

(c) Subject

(d) 50% 

LTR

LTR

referred pain

in pain VAS

1

-

-

+

+

2

-

+

+

+

3

+

+

+

+

4

-

-

+

+

5

-

+

+

+

6

+

+

-

+

7

+

-

+

+

8

+

+

+

-

9

-

+

-

-

10

+

+

-

-

11

-

-

+

+

12

-

-

+

-

13

-

+

+

+

14

-

+

-

+
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Figure 18. sEMG record of snapping palpation of the TrP site and control site, and the TrP injection. The

single vertical dotted line marks the start of the palpation or injection. Double vertical dotted lines mark the

end of the palpation. sEMG 1 around the TrP site is displayed in blue, while sEMG 2 around the control site is

displayed in pink.
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3.4. Presence or absence of LTR during the TrP injection based on investigator and subjects’report

LTR was observed in five (36%) of the 14 subjects (Table 7). It was visible and palpable in four of these five subjects,
and was palpable, but not visible, in one subject. In seven of the nine (64%) subjects in whom the LTR was recorded
as absent by the investigator, the pain reduction was more than 50% following the TrP injection (Table 8). Seven of
these nine subjects reported referred pain during the TrP injection (Table 9). Six of the seven subjects who reported
referred pain when the investigator did not observe or palpate the LTR had greater than 50% reduction in pain
intensity following the TrP injection (Table 7). Of the seven subjects in whom the investigator did not observe LTR
but the subject reported referred pain, six had greater than 50% reduction in pain intensity.

Nine (64%) subjects reported that they felt the LTR during the trigger point injection (Table 7). There was poor
agreement between the investigator and the subjects’assessment of the presence or absence of LTR (Table 10). More
subjects reported the presence of LTR (64%) than the investigator (36%) (Table 10). Eight out of ten subjects (80%)
who reported referred pain had more than 50% reduction in pain intensity following the TrP injection (Table 8). Six
out of nine subjects (67%) who reported a LTR had >50% decrease in pain intensity following the TrP injection
(Table 8). Of the subjects who reported referred pain (ten subjects), only half of them reported that the LTR was
present (and vice versa) (Table 10). None of the subjects reported both the absence of the LTR and referred pain
(Table 10).

During the TrP injection, the sEMG tracings of the TrP site (sEMG 1) and the control site (sEMG 2) appeared similar
in subjects 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14. However, the LTR was recorded by the investigator as clinically
visible and palpable in subjects 3, 7, 8, and 10, and subjects 2, 3, 5, 8, 9, 10, and 14 recorded that they felt the LTR.
Hence, in subjects 3, 8 and 10, in whom both the investigator and subject agreed that an LTR was present during the
TrP injection, the sEMG tracing did not show a corresponding burst of activity at the electrode around the TrP (sEMG
1) relative to the control electrode (sEMG 2).
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Table 8. Relationship between the investigator and subjects’report of presence ‘
+’or absence ‘
-’of LTR and
subjects’report on perceived referred pain, and pain reduction following TrP injection.
50% in pain intensity

<50% in pain intensity

Investigator LTR +

3 (21%)

2 (14%)

Investigator LTR -

7 (50%)

2 (14%)

Subject LTR +

6 (43%)

3 (21%)

Subject LTR -

4 (29%)

1 ( 7%)

Subject referred pain +

8 (57%)

2 (14%)

Subject referred pain -

2 (14%)

2 (14%)

Table 9. Comparison of subjects’perception of referred pain with investigator’
s record of the LTR.

Subject
Referred pain +

Referred pain -

Total

Investigator LTR +

3 (21%)

2 (14%)

5 ( 36%)

LTR -

7 (50%)

2 (14%)

9 ( 64%)

10 (71%)

4 (29%)

14 (100%)

Total

Table 10. Investigator and subjects’observation of the presence ‘
+’or absence ‘
-’of the LTR, and subjects’
perception of referred pain during the TrP injection.
Subject
LTR +

LTR -

Investigator LTR +

4 (29%)

1 ( 7%)

Investigator LTR -

5 (36%)

4 (29%)

Subject referred pain + 5 (36%)

5 (36%)

4 (29%)

0 ( 0%)

Subject referred pain -
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3.5. Subject’
s evaluation of the presence or absence of referred pain during the TrP injection

Ten (71%) subjects indicated that they felt referred pain during the TrP injection. Based on these subjects’pain
diagrams, in nine of the ten subjects (except subject 11), the referred pain regions felt during the TrP injection
coincided with the referred pain regions felt during the investigator’
s palpation of the TrP (see Figure 19). Table 8
shows that eight out of ten subjects who experienced referred pain during the TrP injection reported a greater than
50% reduction in pain intensity following the injection.
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Figure 19. Pain diagrams of subjects 1 to 14.
(a) subject indicates her area of pain at initial evaluation
(b) area of referred pain, if any, indicated by the subject during palpation of the TrP
(c) area of referred pain, if any, indicated by the subject during the TrP injection.

(a)

(b)

Subject 1

Subject 2

Subject 3

Subject 4

Subject 5

Subject 6

Subject 7
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(c)

Figure 19 (continued)

Subject 8

Subject 9

Subject 10

Subject 11

Subject 12

Subject 13

Subject 14

31

3.6. Final pain intensity
An immediate pain reduction of 50% was considered a positive response 94. The mean final pain intensity was 2/10
(s.d. = 1.75), ranging between 0 –5/10. Three (21%) subjects reported that they had no pain. Ten (71%) subjects
reported 50% reduction in their pain. Four (29%) subjects had <50% reduction of their pain (44%, 38%, 25%, and
0%). Of the 14 subjects in this study only one (7%) subject reported no change in her pain. There was a statistically
significant reduction in pain intensity (mean decrease = 3.57/10; s.d. = 1.74) (t-test; p<0.001) after the trigger point
injection.

3.7. Complications or adverse reactions

No subject reported any complications or adverse reactions.

Copyright 2004, Pei Feng Lim
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4. Discussion

4.1 Study design

This study was similar in design to several nEMG studies investigating the electrophysiological characteristics of
myofascial TrPs

31 32 30 35 34 36

. In these studies, a needle electrode was inserted into the active TrP and a second

needle electrode (control) was inserted into the same muscle, but outside the taut band. In our study, one set of sEMG
electrodes was placed around the TrP (sEMG 1) and another set placed around a control site on the same muscle but
2cm away from the taut band (sEMG 2). This is the first study, to date, which compared muscle activity at a TrP
versus a control site on the same muscle using sEMG.

4.2. sEMG recording

During the five second voluntary contraction of the trapezius muscle, the mean sEMG activity at the control site
(sEMG 2) showed a 3-fold increase, while that at the TrP site (sEMG 1) showed a 7.5-fold increase, compared to the
respective mean baseline resting activity. This is in agreement with Donaldson et al 95 who, using dynamic sEMG
techniques, found that muscles with TrPs generated more electrical activity than those without TrPs when performing
the same movement.

Comparing the baseline resting muscle activity to the final resting muscle activity, only the control site (sEMG 2)
exhibited a statistically significant decrease in the muscle activity (p = 0.008) (muscle activity at the TrP site
decreased slightly, but did not reach a level of statistical significance). We speculate that this could be due to small
numbers of subjects in our study (n=14). The decrease in activity agrees with Hendler et al

76

who reported a

statistically significant decrease in trapezius muscle activity measured using sEMG following a TrP injection in the
same muscle. Carlson et al 49 reported reduction in resting sEMG activity in masseter muscles (site of pain) after TrP
injection in the trapezius muscle (source of pain). Perhaps this decrease in activity is a result of reduction in pain
intensity. But Graff-Radford et al 96 investigated the effect of Transcutaneous Electrical Nerve Stimulation (TENS) in
myofascial TrPs, and found that pain reduction was not associated with changes in TrP sensitivity measured by
algometry. Also, in our study, subjects reporting higher initial pain intensity had statistically significantly lower mean
sEMG activity at the TrP site, but not at the control site.
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Snapping palpation of the TrP site resulted in a statistically significant increase in mean muscle activity from the
baseline resting activity (p=0.013) at the TrP site, but not at the control site. These findings agree with Fricton et al 26
who, using nEMG in 16 subjects, found significantly higher muscle activity (p 0.001) in the TrP than in normal
muscle during snapping palpation of the TrP. They found no significant increase in nEMG activity during palpation of
the control site. In addition, in our study, snapping palpation of the control site did not result in any statistically
significant change in muscle activity both at the TrP (sEMG 1) and the control sites (sEMG 2).

No trend was observed in the sEMG 1 or sEMG 2 tracings during snapping palpation of the TrP and control sites, and
during the TrP injection. This study is in agreement with previous studies that found that the LTR produced by
snapping palpation 85
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and needling 27 could not be recorded by sEMG. However, the sample sizes in these studies

were very small and these studies did not include a control sEMG electrode on the same muscle. We felt that an
increase or burst of activity at the TrP site, but not the control site, would be representative of the LTR occurring at
the TrP site. In this study, however no such differences were found. In fact, the LTR was recorded as clinically
present by investigator and subject, and appeared to be positive on sEMG in only 1 subject (subject 6). In subjects 3, 8
and 10, in whom both the investigator and subject agreed that an LTR was present during the TrP injection, the sEMG
tracing did not show a corresponding burst of activity at the electrode around the TrP (sEMG 1) relative to the control
electrode (sEMG 2). Perhaps the nature of the twitch response is so small that sEMG is unable to register its
occurrence. Our sEMG recording was accurate in recording muscle activity at rest, during tension and contraction,
and yet unable to record this minute muscle response.

4.3 TrP injection and the LTR

Although the number of LTRs elicited during each TrP injection was not recorded in this study, LTRs observed by the
investigator numbered no more than 1-2 twitches when they occurred. Chen et al
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recorded a mean of 30.2 4.7

LTRs elicited during rapid needling, and a mean of 8.4 1.4 LTRs elicited during slow needle insertion into rabbit
TrSs. Irnich et al 47 investigated the effect of dry needling in myofascial TrPs and upon needle insertion, manipulated
the needle until at least one LTR was elicited. In Hong’
s study 17 investigating the effect of lidocaine injection (n=35)
versus dry needling (n=23), needling was continued until no more LTR were elicited after 10-20 needle insertions. In
subjects with the LTR, 5-30 LTRs were reportedly elicited from 20-60 needle insertions into each TrP. In cases where
no LTR was elicited during the first injection or dry needling, further needling was carried on in an attempt to elicit
LTRs “
for ethical considerations”because Hong believed that failure to elicit the LTR would compromise the
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treatment outcome. In our study, during the TrP injection, the investigator reported LTR in only 36% of the subjects,
while 64% of the subjects reported that they felt the LTR, and the sEMG recorded only one LTR in one subject. The
investigator was blinded to the number of LTRs perceived by each subject and the number of needle insertions was
not counted. Subtle differences in the needling technique might account for the low numbers of LTRs elicited in our
study compared with the high numbers of LTRs elicited in Hong’
s study despite the fact that both studies used the
fast-in-fast-out technique described by Simons et al 2. For example, the number of LTRs elicited may be influenced
by the speed, force and number of needle penetration in and out of the TrP. The duration of needling might also be an
important variable. Discrepancy between the LTRs reported by the investigator and that experienced by the subjects
could be a result of some subjects misinterpreting the initial needle penetration or the needling as the LTR. Other
subjects could be unfamiliar with what a LTR felt like or were eager to report a LTR simply because they were
participating in a study that investigated the LTR and wanted to please the investigator with an affirmative response.

Hong

17

observed that there was little or no immediate treatment effect if no LTR was elicited (n=17). It would be

interesting to look at the pain levels in those subjects (where LTR was absent) 2 weeks later. However, these data
were not collected in the study. The results of our study shows that despite the low percentage of LTRs elicited
clinically (36%), a large number of subjects (71%) reported more than 50% immediate reduction in pain intensity
after the TrP injection. These data are in direct conflict with the literature reporting the importance of eliciting the
LTR during TrP injections in reducing myofascial pain. Further research and longitudinal data are needed to establish
whether or not a LTR is indeed a requirement for successful trigger point injections.

4.4. Referred pain

In this study, the area of referred pain on palpation of the TrP in the upper trapezius muscle was consistent with that
described by Travell and Rinzler

97

and Wright

98

. Wright

98

investigated the referred pain pattern in 230 TMD

patients and found that the trapezius muscle most commonly referred to the frontal, periorbital and occipital regions.
Fricton et al 99 added that 63% of the subjects with jaw pain (n=104) had an active TrP in the trapezius muscle that
referred pain to their jaw. They also found that TrPs in the trapezius muscle could refer pain to the teeth. Twenty-nine
percent of the subjects in our study had jaw pain, but none reported referred pain to their teeth.

During the TrP injection, 10 subjects reported referred pain. Eight of them had more than 50% reduction in pain
intensity following the TrP injection. In our study, self-reported referred pain was most predictive of immediate
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reduction in pain intensity. The high success rate (50% reduction in pain intensity) in this cohort was a surprise
considering that in our experience in clinical practice, patients usually have more than one active TrP responsible for
the referred pain. We suspect this to be true for some of the subjects in this cohort.

4.5. Immediate pain reduction following the TrP injection

There was a statistically significant (p<0.001) reduction in reported mean pain intensity after the trigger point
injection. Several factors could account for this pain reduction. Firstly, post injection hemostasis might be a form of
acupressure. Garvey et al

46

reported that 66% of the subjects (n=16) who were randomized to a 10 second ethyl

chloride spray followed by 20 seconds of acupressure on their lower back trigger points reported reduction in their
lower back pain, compared to only 40% of the subjects (n=13) who received trigger point injections. Hou et al 100 also
reported that ischemic compression of TrPs using either 90s of lower pressure or 30s of high pressure resulted in
immediate pain relief. Secondly, resting for 5 minutes before and 5 minutes after the TrP injection, with the subjects’
teeth apart and jaw relaxed, helped to promote muscle relaxation and the relaxation may have resulted in reduction of
muscle pain. Thirdly, subjects may have felt a release from apprehension from having completed the injection as
suggested by Carlson et al 49. Fourthly, the pain reduction could be a placebo response. There was no control group in
this study. Cummings and White 55 in a systematic review of 23 papers on needling therapies in myofascial pain, did
not find any evidence that needling therapies have an effect beyond placebo. They concluded that “
no technique is
better than any other”and recommended that the method safest and most comfortable for the patient be used. Fifthly,
regression to the mean

101

could play a role in the pain reduction. Subjects in this study presented with moderate

initial pain intensity (mean of 5.6/10). Scicchitano et al

81

suggested that treatment is more likely to have an

appreciable impact on the patient if the pain is severe enough for a clear reduction in pain to be experienced at the
time of treatment.

Finally, psychological and other factors can affect treatment outcome. Scicchitano et al

81

studied the factors

associated with excellent (n=23), partial (n=19) and poor (n=8) immediate response following TrP injections. They
found that subjects reporting partial improvement had moderate-severe pain, acknowledged more stressors expressed
as significantly lower scores on Denial scale of the Illness Behaviour Questionnaire (IBQ), and had greater difficulty
expressing their feelings (significantly higher scores on Affective Inhibition scale of the IBQ), especially negative
emotions, than the other two groups. They also reported that the greater the difficulty patients experienced in
expressing their feelings, especially negative ones, the more likely their response to TrP injection would be short-
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lived. Thus, patients who strongly denied current life stresses and had a tendency to focus on physical illness
responded poorly to the TrP injections. Hopwood and Abram 78 investigated the factors associated with the failure of
TrP injections in 193 subjects over a time period of at least 2 weeks. They found that an increased risk of treatment
failure was associated with unemployment due to pain at the start of treatment, no relief from analgesics, constant
pain, high levels of pain, prolonged pain, change in social activity, and lower levels of coping ability. On the contrary,
Esenyel et al

50

reported that the presence of depression (in 22.9% of their subjects) or anxiety (in 89.3% of their

subjects) did not limit the effect of physical modalities or TrP injection on pain reduction at 2 weeks and 3 months
post treatment. These studies suggest that the patient’
s attitude towards his illness may have a greater influence on
treatment outcome rather than the presence of psychopathology.

4.6. Limitations of this study

Several limitations deserve mention in this study. Firstly, this cohort consisted of only females. This was partly
related to the ease of recruitment of females since there were more females than males seen in our clinic population.
Secondly, this study sample was very small (n=14). Still, the fact that the sEMG could only record one out of five
clinically observed and nine subjectively reported LTRs (during TrP injection) showed that the instrument has very
poor ability to detect this muscle response. Thirdly, during the TrP injection, it is possible that the increase in activity
at the TrP site resulted from the application of pressure by the investigator’
s fingers when trapping the taut band. To
investigate this possibility, the same injection technique needs to be administered at the control site to determine if
there was a similar increase in muscle activity at the control site. And in this case, to avoid bias, the investigator
should be blinded to the location of the TrP and the control sites. Fourthly, this study involved only one investigator.
Simons 12 stated that much skill was required to elicit the LTR by snapping palpation and needling. It is possible that
the number of LTRs elicited may be different if the TrP injection was carried out by different investigators. Elicitation
of the LTR is technique sensitive and inter-investigator reliability for detecting the LTR is low whether or not the
examiner is trained
study

17

24 6 23

. This may explain the low numbers of LTRs elicited in this study compared with Hong’
s

. Finally, subjects with other active TrP referring to the site of pain complaint were not excluded. The four

subjects who reported less than 50% reduction in pain intensity following the TrP injection might have had sources of
pain from other active TrPs or cervical structures (e.g. intervertebral discs 102). The latter is possible because although
subjects with cervical spine injury or surgery were excluded, we did not conduct a cervical spine examination to rule
out objective findings of cervical spine disorders. Nevertheless, this study was designed to characterize the LTR and
not to measure treatment outcome.
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4.7. Recommendations

Future researchers should take into consideration the limitations raised in the discussion segment of this report (see
section 4.7. Limitations of this study) in order to improve on study design for investigating the LTR. The results of
this study need to be confirmed in a larger number of subjects. Our study suggests that sEMG is unable to capture the
LTR. Yet objective measurement or record of the LTR is important in order to avoid observer bias. For now, nEMG
might be the instrument of choice when it comes to studying the LTR phenomena. Further investigations into the
techniques of eliciting the LTR (such as whether the rapidity of needling influence the ability to elicit LTRs), the
factors which determine its presence, magnitude and frequency of occurrence, and its presence in asymptomatic
muscles will contribute to the understanding of this unique muscle response. The therapeutic role of the LTR also
remains to be determined.

Copyright 2004, Pei Feng Lim
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5. Conclusion

This paper reported the preliminary findings on the inability of sEMG to register the LTR elicited by snapping
palpation and TrP injection in a series of 14 female subjects with myofascial pain.

During the TrP injection, the investigator reported LTR in only 36% of the subjects, while 64% of the subjects
reported that they felt the LTR, and the sEMG possibly only recorded one LTR in one subject. Despite the low
percentage of LTRs elicited clinically (36%), a large number of subjects (71%) reported more than 50% immediate
reduction in pain intensity after the TrP injection. Further research is needed to investigate the therapeutic effect of the
LTR.

Copyright 2004, Pei Feng Lim
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